Teva and Prestige Biopharma enter license agreement for Tuznue (trastuzumab biosimilar) commercialization in Europe
Teva Pharmaceutical Industries Ltd. entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin, across a majority of European markets…. read more.
